Drugs / OLP-1002
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03760913 | Nov 2018 → Oct 2020 | — | OliPass Corporation | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04677933 | Jun → Dec 2020 | osteoarthritis | OliPass Australia Pty Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05216341 | Jan 2021 → Sep 2023 | osteoarthritis | OliPass Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-11-20 | OliPass Corporation | Results OLP-1002 임상1b상 및 임상2a상 임상 결과에 대한 종합 분석 olipass.com ↗
OLP-1002 임상1b상 및 임상2a상 임상 결과에 대한 종합 분석 내용을 첨부파일로 안내드리오니 참고해 주시기 바랍니다. |
| 2023-11-14 | OliPass Corporation | Results 호주임상2a상 관련 영문기사 olipass.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-20 | OliPass Corporation | OLP-1002 임상1b상 및 임상2a상 임상 결과에 대한 종합 분석 olipass.com ↗ |
| 2023-11-14 | OliPass Corporation | 호주임상2a상 관련 영문기사 olipass.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLP-1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05216341 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg” NCT03760913 ↗ |